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Abstract Vitronectin is a multifunctional serum protein which 
provides a unique regulatory link between cell adhesion, humoral 
defense mechanism and the hemostatic system, and the heparin-
binding properties of vitronectin are thought to have participated 
in various functional aspects. In addition to the carboxy-terminal 
glycosaminoglycan-binding motif, we report on two novel 
heparin-binding domains which were identified using phage 
display technique. One heparin-binding domain is located 
between amino acids Asp8 and Cys13 at the end of the 
connector region, while the other is in the second hemopexin-type 
repeat, between amino acids Lys1 7 5 and Asp2 1 9 of the vitronectin 
molecule. Our findings may shed new light to the activities of 
vitronectin and its binding to cells, which could not be explained 
solely on the basis of the known heparin-binding domain. 
© 1997 Federation of European Biochemical Societies. 
1. Introduction 
Vitronectin is a multifunctional serum protein produced 
primarily in the liver and originally defined as S-protein or 
serum-spreading factor [1]. Vitronectin affects the humoral 
immune system by binding to and inhibiting the complement 
C5b-9 membrane attack complex [2]. As a major matrix-asso-
ciated adhesive glycoprotein, it regulates blood coagulation on 
the basis of its ability to bind heparin, plasminogen, plasmi-
nogen activator inhibitor-1 and thrombin-inhibitor complexes 
[3,4]. Within vitronectin, distinct interactive sites for these 
components were identified, whose exposure may depend on 
the conformation of the vitronectin molecule. Studies on 
structural requirements for neutralization of heparin-like sac-
charides by vitronectin suggested that vitronectin might inter-
act through its glycosaminoglycan binding domain(s) with 
various functional sites of the heparin molecule [5,6]. The 
phenomenon of heparin neutralization is interpreted primarily 
in terms of a direct interaction between the highly basic region 
of the vitronectin molecule comprised by amino acid residues 
Ala 3 4 1-Arg 3 7 9 and various regions of the polysaccharide chain 
[6,7]. Evidence compatible with the participation of the pro-
posed glycosaminoglycan binding domain of vitronectin is 
provided by the demonstration of heparin neutralization by 
a synthetic tridecapeptide (amino acids Lys3 4 8-Tyr3 6 0) [4,6]. 
However, the interaction of this synthetic peptide with hepa-
rin is weaker than that of the protein. In addition, while 
vitronectin can largely neutralize the anti-Factor Xa activity 
of the synthetic heparin antithrombin-binding pentasacchar-
ide, the tridecapeptide is unable to function in this respect [6]. 
These findings point to amino acid sequence(s) of vitronectm 
other than that of Lys3 4 8-Tyr3 6 0 playing a contributory role in 
»Corresponding author. Fax: (49) 531-391-5858. 
E-mail : gsc@gbf-braunschweig.de 
heparin neutralization. In the present study, by using phage 
display technique, we have identified two novel heparin-bind-
ing domains of vitronectin. 
2. Materials and methods 
2.1. Construction of a vitronectin random epitope phage library 
To generate random fragments encoding epitopes of the vitronectin 
molecule, a 1580 bp DNA fragment containing the full-length vitro-
nectin cDNA [8] was obtained from plasmid pUCVNwt and partially 
digested with DNAase to produce random fragments of 50-100 bp. 
To facilitate the cloning and expression of random DNA fragments, 
we have chosen phagemid vector pComb3B, which contains two non-
selfcomplementary BstXl sites, separated by a 350 bp 'replaceable 
segment', that allow cloning of DNA fragments using BstXI adaptors 
[9,10]. Once cloned in the correct orientation and translation reading 
frame, fragments were expressed as fusion proteins composed of an 
N-terminal pelB leader peptide, a fusion peptide F.^, the epitope pep-
tide, a second fusion peptide F c , a glycine-rich 'flexible' GGGGS 
peptide linker and the C-terminal half of the bacteriophage M13 
gene Ill-encoded minor coat protein cpIII. Upon superinfection 
with a helper phage VSCM13 (Stratagene, Heidelberg, Germany), 
the epitope peptide fused to a part of cpIII were displayed on the 
surface of newly produced phagemid particles [11]. 
2.2. Panning of heparin-binding phagemid particles 
One hundred microliters of heparin-agarose (pore size 0.01 |im) 
(Sigma, Deisenhofen, Germany) were washed 3 times with phosphate 
buffered saline (PBS) and resuspended in 100 ul of PBS containing 3% 
bovine serum albumin (BSA). The suspension was allowed to stand at 
room temperature for 1 h with gentle agitation. Fifty microliters of 
the vitronectin fragment library containing 4.5 X1010 phagemid par-
ticles were mixed with 50 fxl of BSA-blocked heparin-agarose in an 
Eppendorf tube, and the mixture was incubated at room temperature 
for 2 h with gentle agitation. The heparin-agarose beads and bound 
phagemid particles were then spun down using a conventional bench 
centrifuge at 3000 rpm for 3 min. The beads were washed 10 times 
using PBS containing 0.1% Tween 20 (PBST), and the final suspension 
was transferred into a new Eppendorf tube where the beads were 
sedimented by centrifugation and supernatant was discarded. Hepa-
rin-binding phagemid particles were eluted stepwise using 200 JLLI of 
respective buffer, first 0.3 M sodium acetate (pH 5.2), then 0.1 M 
glycine-HCl (pH 2.2). The eluates were immediately neutralized using 
12 ul of 2 M Tris (pH 10). The eluted phagemid particles were then 
used to infect 100 ul of E. coli XL-1 Blue (Stratagene), which were 
subsequently spread onto Luria-Bertani agar plates containing 50 ug/ 
ml carbenicilin and 10 ug/ml tetracyclin for overnight incubation at 
37°C. 
In preliminary experiments, 50 ul of the vitronectin phage library 
(containing 4.5 X 1010 phagemid particles) were added onto microtiter 
wells coated with 3% BSA. After 10 times washing with PBST, no 
phagemid particle was obtained using the elution steps described 
above. The possibility of vitronectin phage library binding to the 
blocking agent BSA was therefore excluded. 
2.3. Sequencing of DNA inserts 
Individual clones, harboring recombinant phagemids from the pre-
vious step, were picked and cultivated with gentle shaking at 37°C 
overnight in 5 ml of Luria-Bertani broth containing antibiotics as 
above. Phagemids containing a vitronectin cDNA fragment were pu-
rified according to the QIAprep Spin Plasmid Kit Protocol (QIA-
GEN, Hilden, Germany). The sequences of the inserts were deter-
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Fig. 1. Alignment of vitronectin cDNA fragment-encoding peptides, which were displayed as cpIII fusion protein on the surface of M13 phages 
and bearing heparin-binding activity. Amino acid sequences Asp82-Cys137, Lys175-Asp219, and of all 15 phage-displayed vitronectin peptides are 
shown. 
mined according to the ABI PRISM™ DYE Terminator Cycle Se-
quencing Ready Reaction Kit Protocol (PERKIN-ELMER), using an 
ABI automatic sequencer. The following two synthesized oligonucleo-
tides were used as primers: 5'-GCCCAGGTGAAACTGCTCG-3' 
and 5'-CAAACGAATGGAGAGCCACC-3'. A computer program 
'Genework' was used to analyze the obtained sequences. Estimation 
of pi values of the displayed peptides encoded by a vitronectin cDNA 
fragment was made using the same computer program. 
and approximately 0.01% hydrogen peroxide as recommended by the 
manufacturer. The reaction was stopped using 50 ul of 1 M H2SO4, 
and the plates were then read at 490 nm with a Bio-Rad ELISA 
reader. Several repetition of duplicate determinations were made 
and averaged in all cases. 
3. Results 
2.4. Microtiter plate binding assay 
Three representative heparin-binding phagemid clones H24-2.2 (en-
coding vitronetin peptide Asp82-Glu100), H25-2.2 (encoding vitronec-
tin peptide Asp117-Pro130) and H58-2.2 (encoding vitroenctin peptide 
Lys175-Asp216) were selected, and their corresponding phagemid par-
ticles were propagated and tested for their ability to bind to immobi-
lized heparin. Briefly, 96-well microtiter plates were coated with hep-
arin-albumin (Sigma) at a concentration of 20 u.g/well in 100 j_il of 
PBS at 4°C overnight. Additional binding sites were blocked using 3% 
BSA in PBST for 1 h at 37°C. A series of concentrations of phagemid 
particles in 100 u.1 were added and the plates were incubated for 1 h at 
37°C. After six washes of the microtiter plates with PBST, bound 
phagemid particles were detected using horseradish peroxidase conju-
gated to sheep anti-M13 polyclonal antibodies (1:5000, Pharmacia 
Biotech). The plates were developed for 20 min with o-phenylenedi-
amine dihydrochloride in 0.1 M citric acid-phosphate buffer (pH 5.0) 
3.1. Construction of a vitronectin fragment phage display 
library 
A vitronectin random peptide library was constructed con-
taining approximately 105 independent clones and having a 
titer of 9X 1011 phagemid particle/ml. Fifty randomly picked 
clones were sequenced, revealing inserts in the designated 
range with equal participation of both orientations and a 
non-biased distribution of fragments throughout the vitronec-
tin cDNA. Approximately one in 18 inserts expressed a vitro-
nectin peptide (data not shown). 
3.2. Affinity selection of heparin-binding phagemid particles 
After stringent washing with PBST, bound phagemid par-
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Fig. 2. Distribution of pi values of 100 heparin-binding peptides, se-
lected from the vitronectin random peptide phage library by pH 2.2 
elution. The computer-assisted estimation of p / values was based on 
the sequence of the vitronectin cDNA inserts. Vn ORF: vitronectin 
open reading frame. 
tides were eluted from the heparin-agarose stepwise by low-
ering the pH. After pH 5.2 elution, approximately 104 phag-
emid particles, reflected by carbenicilin resistant colonies, were 
obtained. Eighty recombinant phagemids were selected ran-
domly and inserts were sequenced. By pH 2.2 elution, a total 
of 200 phagemids were obtained, and 160 of them were se-
lected randomly and inserts were sequenced. In control experi-
ments, where helper phages containing the phagemid vector 
pCom3b without a insert were used to pan against heparin-
agarose beads, no carbenicilin resistant colony was obtained. 
3.3. Sequences of the inserts and their alignment against the 
vitronectin gene 
All of the 240 sequenced recombinant phagemids were 
found to have an insert. As clearly shown in Fig. 1, 10 inserts 
(3 from pH 5.2, and 7 from pH 2.2 elution), with correct 
orientation and open reading frame, clustered and many of 
them to some extent overlapped each other between amino 
acid Asp82 and Cys137 of the vitronectin molecule. Similarly, 
all four inserts (1 from pH 5.2, and 3 from pH 2.2) having 
correct orientation and open reading frame, clustered and 
overlapped each other between amino acid Lys175 and 
Asp219 of the vitronectin molecule. Furthermore, one insert 
from pH 5.2 elution aligned itself to the known heparin-bind-
ing domain of vitronectin, at the carboxy-terminus (Pro344-
Ser362). Interestingly, the known heparin-binding region 
Ala341-Arg379 seemed less represented in the experiments. 
However, the estimated pi values indicated that most of the 
heparin-binding peptides, encoded by a vitronectin cDNA 
fragment and displayed on the phage surface, were very basic 
in nature (Fig. 2). 
3.4. Binding of heparin-binding phagemid particles to 
immobilized heparin 
As shown in Fig. 3, phagemid particles from clones H24-
2.2, H25-2.2 and H58-2.2 were able to bind to immobilized 
heparin in a dose-dependent manner. The phagemid particles 
from these three clones did not bind to microtiter wells coated 
with 3% BSA (data not shown). 
4. Discussion 
The phage display technique, introduced in 1985 by Smith 
[12], utilizes filamentous Ml3 phages to express foreign pep-
tides or proteins in fusion with one of the coat proteins. Dur-
ing the past decade this technique has been developed into a 
powerful method to study protein-ligand interactions [13]. 
Epitope libraries have been constructed and used to identify 
specific amino acids involved in protein-protein interactions, 
such as the RGD-motif recognized by integrins [14], and epi-
topes in proteins recognized by antibodies [15]. Other large 
peptides that have been successfully displayed in the native 
conformation are the enzyme, alkaline phosphatase, and an 
immunogenic fragment of the HIV Gag protein [see reviews 
[13] and [16]], as well as plasminogen activator inhibitor-1 
[17]. The so-called panning procedure in fact is an affinity 
purification of fusion protein, and the advantage of phage 
display cloning lies in the physical linkage of each protein 
to the genetic material that encodes it. 
As a cell adhesion and spreading factor, vitronectin has 
been identified in the extracellular matrix and isolated from 
plasma and serum [see review [1]]. Its interactions with hep-
arin and cellular receptors were documented by several studies 
emphasizing the importance of conformationally different iso-
forms [18]. The well-documented heparin-binding site is com-
prised of a cluster of basic residues between Arg341 and Arg379 
[8]. More than 40% of the amino acids in this sequence are 
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Fig. 3. Binding of heparin-binding phagemid particles to immobilized heparin. Background values of each phagemid particle concentration, esti-
mated using helper phages containing phagemid vector pComb3B without insert, were subtracted. 
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basic, and only a few are hydrophobic, suggesting that this 
region has a loop structure, rather than pronounced a-helix or 
a ß-sheet. Moreover, the core region contains two heparin-
binding consensus sequences that allow tight interactions 
with complementary acidic sites of sulfated glycosaminogly-
cans [7]. It is worth noting that the known heparin-binding 
region Ala341-Arg379 seemed less represented in our experi-
ments. This could be explained by the fact that most hepa-
rin-binding peptides, displayed on the phage surface and se-
lected by panning, were very basic in nature as judged by their 
pi values (Fig. 2). Subsequently, these basic peptides could 
compete with the peptides corresponding to the known hep-
arin-binding domain. In contrast, no other sequences with 
clusters of basic amino acids are present in vitronectin. 
Thus, both regions Asp82-Cys137 and Lys175-Asp219, where 
two novel heparin-binding domains were proposed based on 
this communication, provide a different type of interaction 
with glycosaminoglycans that is reminiscent to the interaction 
of heparin with antithrombin [19] or the NH2-terminus of 
human plasma fibronectin [20]. In these proteins the organi-
zation of proposed loops together with hydrophilic and flex-
ible segments results in the provision of several arginine- or 
lysine-containing sites for potential interaction with the sulfate 
groups of heparin. Similarly, folding of the protein backbone 
in vitronectin mostly within 8-sheet structures and loops, as 
proposed by secondary structure prediction [5], may bring 
basic residues in close proximity into functional heparin bind-
ing site(s) that were previously not recognized. 
Indeed, several observations point to the fact that heparin-
binding properties of native vitronectin are different from the 
well-known binding of glycosaminoglycans to the C-terminal 
basic cluster, which is normally buried in this conformational 
state but becomes accessible following denaturation/unfolding 
and/or multimer formation of vitronectin [5,6,21]: (a) at low 
ionic strength, native vitronectin is retained on immobilized 
heparin together with a <~40 kDa NH2-terminal fragment 
lacking the basic cluster [22]; (b) differences in the binding 
to and uptake by cells of both forms of vitronectin, which 
are competed for by heparin, have been recognized [23,24]. 
It is tempting to believe that phage surface-displayed vitronec-
tin peptides could resemble the presentation of amino acids in 
their native conformation and that the subsequent overall sur-
face charge in these two regions might account for the hep-
arin-binding activity. 
Finally, the heparin-binding domain(s) of vitronectin are 
involved in the interaction of the adhesive protein with certain 
pathogenic bacteria [25]. The two novel heparin-binding do-
mains described in the present communication might act sep-
arately from or synergistically with the known C-terminal 
heparin-binding site and thereby dictate conformation-de-
pendent heparin neutralization activities of vitronectin as 
well as cell surface receptor interactions also relevant in bac-
terial pathogenesis. 
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